CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.Older patients appeared to derive better OS and PFS outcomes with immunotherapy alone, findings from the exploratory pooled analysis showed.